Eugene I Hwang

List of Publications by Year
in descending order

58	1,929	361413	315739
papers	citations	20 h-index	38 g-index

59	59	59	3191
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
2	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197
3	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
4	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathologica, 2014, 128, 291-303.	7.7	141
5	Longâ€term efficacy and toxicity of bevacizumabâ€based therapy in children with recurrent lowâ€grade gliomas. Pediatric Blood and Cancer, 2013, 60, 776-782.	1.5	114
6	Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. JAMA Ophthalmology, 2014, 132, 111.	2.5	100
7	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
8	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	7.0	84
9	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
10	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
11	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	7.7	65
12	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	7.1	61
13	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Childrenâ€™s Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	1.6	58
14	Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. JAMA Ophthalmology, 2014, 132, 265.	2.5	57
15	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	1.2	44
16	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44
17	Medulloblastoma rendered susceptible to NK-cell attack by TGFÎ² neutralization. Journal of Translational Medicine, 2019, 17, 321.	4.4	32
18	Treatment of pediatric cerebral radiation necrosis: a systematic review. Journal of Neuro-Oncology, 2016, 130, 141-148.	2.9	26

#	Article	IF	Citations
19	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	1.5	24
20	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.6	22
21	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
22	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
23	Î”Np73/ETS2 complex drives glioblastoma pathogenesisâ€” targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. Neuro-Oncology, 2020, 22, 345-356.	1.2	20
24	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatric Blood and Cancer, 2018, 65, e26832.	1.5	13
25	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2021, 27, 2442-2451.	7.0	13
26	IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045). Neuro-Oncology, 2018, 20, i100-i100.	1.2	11
27	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Childrenâ€™s Oncology Group ACNS0332 Trial. American Journal of Neuroradiology, 2019, 40, 1796-1803.	2.4	11
28	Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. Paediatric Drugs, 2020, 22, 45-54.	3.1	7
29	Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. Pediatric Blood and Cancer, 2020, 67, e28478.	1.5	7
30	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. Scientific Reports, 2020, 10, 10954.	3.3	7
31	The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib. Neuro-Oncology Advances, 2021, 3, vdab022.	0.7	7
32	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget, 0, 7, 42837-42842.	1.8	7
33	Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 205-219.	2.8	5
34	PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. Neuro-Oncology, 2018, 20, vi201-vi202.	1.2	4
35	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	1.2	4
36	Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib. Neuro-Oncology, 2022, 24, 1029-1031.	1.2	4

#	Article	IF	Citations
37	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. Pediatric Neurology, 2020, 107, 7-15.	2.1	2
38	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii391-iii391.	1.2	2
39	QOLP-24. PATIENTSâ€™/PARENTSâ€™ EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. Neuro-Oncology, 2019, 21, vi202-vi203.	1.2	1
40	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. Neuro-Oncology, 2022, 24, i85-i86.	1.2	1
41	Experimental Therapeutic Trial Design for Pediatric Brain Tumors. Journal of Child Neurology, 2016, 31, 1421-1432.	1.4	0
42	EPID-08. THE CURRENT LANDSCAPE OF THERAPEUTIC CLINICAL TRIALS IN PEDIATRIC BRAIN TUMORS: A REVIEW OF CLINICALTRIALS.GOV. Neuro-Oncology, 2018, 20, i81-i82.	1.2	0
43	CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. Neuro-Oncology, 2018, 20, i39-i40.	1.2	0
44	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. Neuro-Oncology, 2018, 20, i68-i69.	1.2	0
45	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	1.2	0
46	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. Neuro-Oncology, 2019, 21, ii81-ii82.	1.2	0
47	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro-Oncology, 2019, 21, vi192-vi192.	1.2	0
48	EMBR-08. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON â€œHEAD STARTâ€•4 CLINICAL TRIAL. Neuro-Oncology, 2021, 23, i7-i7.	1.2	0
49	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. Neuro-Oncology, 2021, 23, i6-i6.	1.2	0
50	EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. Neuro-Oncology, 2020, 22, iii304-iii304.	1.2	0
51	MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON â€œHEAD STARTâ€•4 CLINICAL TRIAL. Neuro-Oncology, 2020, 22, iii390-iii390.	1.2	0
52	EPCT-16. A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA. Neuro-Oncology, 2020, 22, iii306-iii307.	1.2	0
53	IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). Neuro-Oncology, 2020, 22, iii361-iii361.	1.2	0
54	EPCT-17. A PHASE I AND SURGICAL STUDY OF RIBOCICLIB AND EVEROLIMUS IN CHILDREN WITH RECURRENT OR REFRACTORY MALIGNANT BRAIN TUMORS: PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT. Neuro-Oncology, 2020, 22, iii307-iii307.	1.2	0

#	Article	IF	Citations
55	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. Neuro-Oncology, 2020, 22, iii327-iii327.	1.2	0
56	LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	0
57	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	1.2	0
58	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i36.	1.2	0